>>Signaling Pathways>> DNA Damage/DNA Repair>> Deubiquitinase>>FT827

FT827

Catalog No.GC32917

FT827는 선택적 및 공액성 유비퀴틴 특이 프로테아제 7 (USP7) 억제제입니다 (Ki = 4.2 ?M). FT827은 USP7 촉매 도메인 (USP7CD; 잔여물 208-560)에 표면 Kd 값이 7.8 ?M으로 결합합니다.

Products are for research use only. Not for human use. We do not sell to patients.

FT827 Chemical Structure

Cas No.: 1959537-86-0

Size 가격 재고 수량
10mM (in 1mL DMSO)
US$832.00
재고 있음
5mg
US$689.00
재고 있음
10mg
US$1,103.00
재고 있음
25mg
US$2,206.00
재고 있음
50mg
US$3,585.00
재고 있음
100mg
US$5,424.00
재고 있음

Tel:(909) 407-4943 Email: sales@glpbio.com

고객 리뷰

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Protocol Chemical Properties Product Documents Related Products

FT827 is a selective and covalent ubiquitin-specific protease 7 (USP7) inhibitor with an IC50 of 52 nM.

FT827 features a vinylsulfonamide moiety that covalently modifies the catalytic Cys223 of USP7 and inhibits the enzyme with Ki and Kd of 7.8 and 4.2 μM, respectively. FT827 exclusively inhibit USP7 in a panel of 38 deubiquitinases (DUBs) from diverse families. FT827 inhibits USP7 probe reactivity with IC50s of 0.1-2 µM, confirming 10 to 100-fold higher potency as compared to P22077 in crude cell extracts or with intact MCF7 breast cancer cells, followed by incubation with the ubiquitin active site suicide probe haemagglutinin (HA)-tagged ubiquitin bromoethyl (HA-UbC2Br)[1].

[1]. Turnbull AP, et al. Molecular basis of USP7 inhibition by selective small-molecule inhibitors. Nature. 2017 Oct 26;550(7677):481-486.

리뷰

Review for FT827

Average Rating: 5 ★★★★★ (Based on Reviews and 4 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for FT827

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.